Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 23651-95-8 | Product Number: D4235
Droxidopa
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid
- L-threo-3,4-Dihydroxyphenylserine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 50MG |
€100.00
|
1 | 16 |
|
| 200MG |
€287.00
|
1 | 8 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | D4235 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__9H__1__1NO__5 = 213.19 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 200MG-Glass Bottle with Plastic Insert (View image), 50MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 23651-95-8 |
| Reaxys Registry Number | 3206912 |
| PubChem Substance ID | 253659654 |
| Merck Index (14) | 3457 |
| MDL Number | MFCD00799030 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Specific rotation [a]20/D | -38.0 to -43.0 deg(C=0.5、0.1mol/L HCl)(after drying) |
| Drying loss | max. 0.1 % |
Properties (reference)
| Melting Point | 225 °C(dec.) |
| Specific Rotation | -40° (C=0.5,0.1mol/L Hcl) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| Precautionary Statements | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
Related Laws:
| RTECS# | VT9626010 |
Transport Information:
| HS Number | 2922500090 |
Application
Droxidopa: A Prodrug of L-Norepinephrine
Droxidopa (L-DOPS) is a synthetic amino acid analog that is directly metabolized to L-norepinephrine [A0906] by DOPA-decarboxylase (other name: aromatic L-amino acid decarboxylase).
L-norepinephrine is crucial for many processes in the body and brain. Dopamine-β-hydroxylase (DβH) is an enzyme that catalyzed the reaction of dopamine [A0305] to L-norepinephrine. Therefore, DβH deficiency can affects many processes, for example, the autonomic nervous system which controls involuntary body processes such as the regulation of blood pressure and body temperature.
Unlike L-norepinephrine, however, droxidopa easily crosses the blood-brain barrier. Droxidopa is a prodrug of L-norepinephrine, and is used to increase the concentrations of it in the body and brain. Although the exact mechanism of action is unknown, droxidopa is mainly used for the treatment of Parkinson’s disease and neurogenic orthostatic hypotension. (The product is for research purpose only.)
L-norepinephrine is crucial for many processes in the body and brain. Dopamine-β-hydroxylase (DβH) is an enzyme that catalyzed the reaction of dopamine [A0305] to L-norepinephrine. Therefore, DβH deficiency can affects many processes, for example, the autonomic nervous system which controls involuntary body processes such as the regulation of blood pressure and body temperature.
Unlike L-norepinephrine, however, droxidopa easily crosses the blood-brain barrier. Droxidopa is a prodrug of L-norepinephrine, and is used to increase the concentrations of it in the body and brain. Although the exact mechanism of action is unknown, droxidopa is mainly used for the treatment of Parkinson’s disease and neurogenic orthostatic hypotension. (The product is for research purpose only.)
References
- L-threo-3,4-Dihydroxyphenylserine enhanced ocular dominance plasticity in adult cats
- Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine β-hydroxylase
- The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monomania in the human brain: Analysis of the intraventricular fluid from parkinsonian patients
- L-dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug
- Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement (a review)
- Droxidopa in neurogenic orthostatic hypotension (a review)
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.